ArticleMaterials today. Bio2026
Mild photothermal therapy ameliorates neurogenic bladder after sacral spinal cord injury via multi-target effects.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurogenic bladder (NB) is a devastating complication following sacral spinal cord injury (SSCI), often leading to urinary incontinence, recurrent infections, and progressive renal dysfunction, which severely impair patients' quality of life and survival. Current therapeutic options remain largely palliative and fail to reverse the underlying neurogenic pathology. This study employed mild photothermal therapy (MPTT) to treat SSCI-induced NB in rats and systematically investigated its efficacy and mechanisms. Results showed that MPTT effectively improved bladder morphology and urodynamic parameters, with more significant effects observed in early intervention. Mechanistically, MPTT inhibited bladder fibrosis, alleviated chronic inflammation, restored the balance between cell proliferation and apoptosis, promoted functional angiogenesis, and repaired structural damage and function of bladder nerve fibers. MPTT ameliorates SSCI-NB function through multi-target effects, and its time-dependent therapeutic efficacy suggests the necessity of early and repeated interventions, providing experimental and theoretical evidence for new NB treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.